Clinical role of bisphosphonates in the treatment of prostate cancer bone metastases

Research output: Contribution to journalArticle

Abstract

Intravenous bisphosphonates are the current standard of care for patients with multiple myeloma or breast cancer and bone metastases. However, until recently, bisphosphonates had not demonstrated any significant clinical benefit in patients with prostate cancer and bone metastases. Zoledronic acid is the only bisphosphonate to significantly reduce skeletal complications and durably palliate bone pain in patients with advanced prostate cancer. Recently, the use of zoledronic acid for prostate cancer has been approved by the government. In this article, the mechanism and clinical role of zoledronic acid are reviewed.

Original languageEnglish
Pages (from-to)569-574
Number of pages6
JournalNishinihon Journal of Urology
Volume68
Issue number12
Publication statusPublished - Dec 2006

Fingerprint

zoledronic acid
Bone Neoplasms
Diphosphonates
Prostatic Neoplasms
Neoplasm Metastasis
Standard of Care
Multiple Myeloma
Therapeutics
Breast Neoplasms
Bone and Bones
Pain

Keywords

  • Bisphosphonates
  • Prostate cancer
  • SRE (skeletal-related events)
  • Zoledronic acid

ASJC Scopus subject areas

  • Urology

Cite this

Clinical role of bisphosphonates in the treatment of prostate cancer bone metastases. / Nasu, Yasutomo.

In: Nishinihon Journal of Urology, Vol. 68, No. 12, 12.2006, p. 569-574.

Research output: Contribution to journalArticle

@article{db26fe11c98a4bd9a48be687cea9bbd3,
title = "Clinical role of bisphosphonates in the treatment of prostate cancer bone metastases",
abstract = "Intravenous bisphosphonates are the current standard of care for patients with multiple myeloma or breast cancer and bone metastases. However, until recently, bisphosphonates had not demonstrated any significant clinical benefit in patients with prostate cancer and bone metastases. Zoledronic acid is the only bisphosphonate to significantly reduce skeletal complications and durably palliate bone pain in patients with advanced prostate cancer. Recently, the use of zoledronic acid for prostate cancer has been approved by the government. In this article, the mechanism and clinical role of zoledronic acid are reviewed.",
keywords = "Bisphosphonates, Prostate cancer, SRE (skeletal-related events), Zoledronic acid",
author = "Yasutomo Nasu",
year = "2006",
month = "12",
language = "English",
volume = "68",
pages = "569--574",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "12",

}

TY - JOUR

T1 - Clinical role of bisphosphonates in the treatment of prostate cancer bone metastases

AU - Nasu, Yasutomo

PY - 2006/12

Y1 - 2006/12

N2 - Intravenous bisphosphonates are the current standard of care for patients with multiple myeloma or breast cancer and bone metastases. However, until recently, bisphosphonates had not demonstrated any significant clinical benefit in patients with prostate cancer and bone metastases. Zoledronic acid is the only bisphosphonate to significantly reduce skeletal complications and durably palliate bone pain in patients with advanced prostate cancer. Recently, the use of zoledronic acid for prostate cancer has been approved by the government. In this article, the mechanism and clinical role of zoledronic acid are reviewed.

AB - Intravenous bisphosphonates are the current standard of care for patients with multiple myeloma or breast cancer and bone metastases. However, until recently, bisphosphonates had not demonstrated any significant clinical benefit in patients with prostate cancer and bone metastases. Zoledronic acid is the only bisphosphonate to significantly reduce skeletal complications and durably palliate bone pain in patients with advanced prostate cancer. Recently, the use of zoledronic acid for prostate cancer has been approved by the government. In this article, the mechanism and clinical role of zoledronic acid are reviewed.

KW - Bisphosphonates

KW - Prostate cancer

KW - SRE (skeletal-related events)

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=33846534665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846534665&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33846534665

VL - 68

SP - 569

EP - 574

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 12

ER -